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CC BY-NC-ND license (http://creativeAbstract Alzheimer’s disease (AD) remains the most common neurodegenerative disease
characterized by b-amyloid protein (Ab) deposition and memory loss. Studies have shown that
mitochondrial dysfunction plays a crucial role in AD, which involves oxidative stress-induced
respiratory chain dysfunction, loss of mitochondrial biogenesis, defects of mitochondrial dy-
namics and mtDNA mutations. Thus mitochondria might serve as drug therapy target for AD.
In this article, we first briefly discussed mitochondrial theory in the development of AD, and
then we summarized recent advances of mitochondrial abnormalities in AD pathology and
introduced a series of drugs and techniques targeting mitochondria. We think that maintaining
mitochondrial function may provide a new way of thinking in the treatment of AD.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Alzheimer’s disease (AD) is the most common form of
neurodegenerative disease. Patients with AD exhibit
memory loss, declines of problem-solving skills and per-
sonality changes, which not only affect the normal life but
often has fatal prognosis.1 It is estimated that by 2010,
approximately 24 million people worldwide will suffer from3.com (G.-J. Chen).
ity of Chongqing Medical
016.05.001
ng Medical University. Production
commons.org/licenses/by-nc-nd/dementia, most of which are AD. By 2020 there will be 42.3
million people living with AD and other forms of dementia,
and this figure will rise to 81.1 million by 2040.2 AD causes a
huge burden on individuals, families and society, which
would finally translate into extremely high health care
costs. With the increase in life expectancy, AD is becoming
an intractable health problem in aging society.
The pathophysiology of AD is featured by progressive loss
of neurons and synapses, accumulation of amyloid b peptide
(Ab) deposits and intracellular neurofibrillary tangles (NFTs).
Despite the large number of existing research, the patho-
genesis of AD remains to be clarified. The amyloid cascade
hypothesis proposed by Hardy and Allsop3 in 1991 stated that
APP mis-metabolism and beta-amyloid deposition were theand hosting by Elsevier B.V. This is an open access article under the
4.0/).
Mitochondria as a therapeutic target in AD 221primary events in the disease process, yet this hypothesis still
cannot fully explain all the results convincingly. Recent
studies have found amyloid may also present in the brain that
has no clinical manifestations and elevated levels of Ab is not
consistent with the clinical severity of dementia.4 Further,
anti-amyloid drugs in clinical trials do not always benefit
significantly.5 Thus it is still a debate whether amyloidosis in
sporadic Alzheimer’s disease is the primary cause or sec-
ondary to other pathological processes.
Mitochondria exist in most eukaryotic cells, known as the
power plants. In 2004, Swerdlow and Khan proposed mito-
chondrial cascade hypothesis, emphasized the importance of
mitochondrial dysfunction caused by oxidative stress in the
pathogenesis of sporadic AD.6 Mitochondrial cascade hy-
pothesis believes that each individual has inherited a certain
baseline level of mitochondrial function and mitochondrial
durability. Baseline represents the total capacity of mito-
chondrial bioenergetics, while durability determines the rate
of the occurrence of age-relatedmitochondrial dysfunction.7
When mitochondrial declines exceed the threshold, the AD-
related pathological changes such as Ab deposition and
NFTs occur. Ab is thus an epiphenomenon of pathological
development of AD rather than the cause of the disease. This
is consistent with the finding that early mitochondrial
dysfunction can lead to increasedproduction and aggregation
of Ab.8 If mitochondrial durability and functional decay rates
are constant, the time for the occurrence of the disease is
determined by the baseline levels of mitochondrial function.
On the other hand, when mitochondria have a certain base-
line level, the longer mitochondrial function sustain, the
slower the occurrence of age-related decay rates would be.7
These studies suggest that mitochondria might be a very
promising therapeutic target for AD.
Current treatments for AD are not directly targeted to
mitochondria. Cholinesterase inhibitors (donepezil, riva-
stigmine, and galantamine) and N-methyl-D-aspartate re-
ceptor antagonist memantine are the only two kinds of
drugs approved by the FDA for AD treatment,9 which show
only modest clinical symptom improvement. Phase I clinical
trials of anti-amyloid vaccine immunotherapy have been
failed due to a variety of serious adverse drug reactions.10
Over the past few years, the development of b- and g-
secretase inhibitors11 and new vaccines12 has achieved
some encouraging results. However, effective therapy to
slow or halt the progression of AD is still lacking.
Given the importance of mitochondrial dysfunction in
the pathogenesis of AD, new treatment strategies have
been proposed to improve or ameliorate mitochondrial
function. The most challenging problem in the treatment of
mitochondrial dysfunction is not the development of drug
itself, but the lack of a specific targeting medium that
transports drugs to mitochondria and improves their dis-
tribution in mitochondria. In this article, we mainly elab-
orate that mitochondrion is a potential therapeutic target
for AD, and systematically introduce mitochondria-
targeting drugs and related technologies.Mitochondria and oxidative stress
Reactive oxygen species (ROS) including the superoxide
radical (,O2e), hydrogen peroxide (H2O2) and hydroxylradical (,OH) are mainly produced in the mitochondria. In
physiological conditions, the concentration of ROS is
strictly controlled by endogenous antioxidant defense
mechanisms, such as superoxide dismutase, catalase and
glutathione reductase. Excessive intracellular ROS may lead
to oxidative stress and consequent cellular abnormalities.
Most antioxidants protect cells from oxidative damage,
and enhance the efficiency of aerobic metabolism. Drugs
such as coenzyme Q and glutathione can limit the mito-
chondrial ROS production, oxidative stress and reduce
inflammation. While others such as creatine, pyruvic acid
may increase mitochondrial biogenesis. Coenzyme Q10
regulates electron transfer from the complex I & II to
complex III and exhibits some antioxidant effects. Idebe-
none, a synthetic analogue of coenzyme Q10, can effec-
tively penetrate the blood-brain barrier; but it fails to slow
cognitive decline in AD patients in clinical trials.13 Exoge-
nous creatine has been shown to be neuroprotective in vitro
and in vivo experiments since creatine/phosphocreatine
system controlled by mitochondrial creatine kinase plays an
important role in maintaining energy balance in the brain.
Lipoic Acid (LA), a coenzyme of mitochondrial pyruvate
dehydrogenase and a-ketoglutarate dehydrogenase, is also
a powerful antioxidant that can recycle other antioxidants
such as vitamin C and E, glutathione GSH. Study has shown
that long-term dietary LA supplement can ameliorate
learning and memory deficits in Tg2576 mice,14 probably by
improving the recovery of mitochondrial integrity and
functionality and by reducing the number of severely
damaged mitochondria.15 In a study on 43 AD patients LA
effectively slowed the decline of cognitive processes.16
Another recent study of 39 AD patients taking u-3 fatty
acids and LA also reveals consistent results.17
However, it is difficult for the traditional antioxidants
such as coenzyme Q and vitamin E to achieve the desired
effect because of their limited distribution in mitochon-
dria. Efforts have been made to increase the efficacy of
drug targeting, to reduce drug dosage and metabolism
outside mitochondria and the side effects. The most com-
mon way to achieve mitochondrial targeting is to attach
these antioxidants to a lipophilic and cationic triphenyl-
phosphine (TPPþ). In the presence of the lipid-soluble
cationic phenyl group (positively charged) that can bind to
mitochondrial membrane (negatively charged), antioxi-
dants gathered in the mitochondrial matrix may increase by
100e1000 times. However, excessive intake of lipophilic
cations may lead to mitochondrial membrane potential
depolarization, thus this strategy still requires further
study.
Mitochondrial targeting peptide SS (Szeto-Schiller)
selectively accumulated in the mitochondrial inner mem-
brane has an antioxidant effect. By inhibiting the peroxi-
dase activity of cytochrome c/cardiolipin complex, peptide
SS reduces oxidized cytochrome C, and improves mito-
chondrial electron transport and ATP synthesis.18 The most
significant advantage of this peptide is that it does not
change the mitochondrial membrane potential. However,
mitochondrial dysfunction tends to have lower membrane
potential, which might limit the intake of lipophilic cations
that are dependent on membrane potentials. It is reported
that SS-31 reduces b-amyloid protein-mediated cytotoxicity
and improves the neurite outgrowth in the primary neurons
222 J. Wang, G.-J. Chenof APP transgenic mice.19 In addition, this peptide restores
mitochondrial transport and synaptic activity, and reduces
the percentage of abnormal mitochondria,20 suggesting a
potential therapeutic value for AD. Another mitochondria
targeting antioxidant is called Hemigramicidin-2,2,6,6-
tetramethylpiperidine-1-oxyl (Hemigramicidin-TEMPO),
which is composed of two parts, a high affinity for mito-
chondrial membrane gramicidin eS and ROS scavenger
TEMPO. While gramicidin eS can be targeted to mitochon-
dria without depending on membrane potential, TEMPO has
been shown in animal experiments to improve the prognosis
of sepsis-induced acute renal injury,21 yet the effect of this
drug has not been tested in AD.
Alternative mitochondria targeting strategy is to pro-
mote endogenous antioxidant mechanisms (Fig. 1A). Nrf2
(NF-E2-related factor 2) is a transcription factor that reg-
ulates the expression of antioxidant genes through its
interaction with ARE (antioxidant response element).22 It is
known that Nrf2 is significantly reduced in the nucleus of
hippocampal neurons in AD patients.23 In the APP/PS1Fig. 1 Mitochondria targeting strategies in Alzheimer’s diseas
endogenous antioxidative gene expression through Nrf2-ARE pathw
TFAM; C) Maintenance of mitochondrial dynamics by inhibiting D
encoding the normal mtDNA products can be transported to the m
reactive oxygen species, Nrf2: NF-E2-related factor 2, Keap1: Ke
element, PGC1a: peroxisome proliferator-activated receptor gamm
sirtuin 1, TFAM: mitochondrial transcription factor A, drp1:dynam
mfn1/2: mitofusin-1/2.)transgenic mice, Nrf2-ARE activity is gradually attenuated
with Ab deposition; and tert-butylhydroquinone (TBHQ)
application or Nrf2 gene transfer decreases Ab-induced
toxicity.24 In addition, activation of Nrf2 may also promote
the activity of autophagy adapter protein NDP52 (nuclear
domain 10 protein 52) and reduce the level of phosphory-
lated tau.25 Consistently, hippocampal injection of human
Nrf2 gene improves the spatial learning in 9-month-old
APP/PS1 transgenic mice, suggesting a potential thera-
peutic value of Nrf2.26
Curcumin is considered as a Nrf2 agonist and exhibits
antioxidant,27 anti-inflammatory28 and amyloid depolyme-
rizing29 effect in animal experiments. It selectively reacts
with Keap1 (Kelch-like ECH-associated protein 1), an
endogenous inhibitor of Nrf2. The binding of curcumin to
Keap1 promotes Nrf2 dissociation from Keap1, and thus
activates Nrf2.30 However, due to its poor water-solubility
and low bioavailability, curcumin fails to improve cogni-
tion in clinical trials.31 For this reason new delivery
methods have been developed for AD treatment.32 Fore: A) Endogenous antioxidant system agonist that increases
ay; B) Promotion of mitochondrial biogenesis by PGC1-a-NRF-
rp1; D) mtDNA mutations and gene therapy. Exogenous DNA
itochondria resulting in corrections of mtDNA mutations. (ROS:
lch-like ECH-associated protein 1, ARE: antioxidant response
a coactivator 1-a, AMPK: AMP-activated protein kinase, SIRT1:
in-1-like protein, opa1: optic atrophy 1, fis1: fission 1 protein,
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targeted polymeric nanoparticle system (NPs) can signifi-
cantly increase mitochondrial uptake of curcumin. How-
ever, it is worth noting that not all types of nanoparticles
have the ability to enter mitochondrial bilayer membranes,
depending on the size and volume of the surface charge.Mitochondrial biogenesis
Mitochondrial biogenesis plays an important role in main-
taining mitochondrial numbers, cell renewal, adapting to
cell damage and the demand for energy supply.34 This
process is regulated by peroxisome proliferator-activated
receptor (PPAR), and coactivators PGC1a, nuclear respira-
tory factor (NRF) and mitochondrial transcription factor A
(TFAM). PGC1a is a key regulator of mitochondrial biogen-
esis and plays a pivotal role in the energy balance and
metabolism.35 The activity of PGC1a can be regulated by
SIRT1 (sirtuin 1) or AMP-activated protein kinase (AMPK)
respectively.36 Sirtuins (SIRT1-7) are NADþ dependent his-
tone deacetylase protein family members. SIRT1, SIRT6 and
SIRT7 are found in the nucleus, while SIRT2 is mainly
located in the cytoplasm, and SIRT3-5 are in mitochon-
dria.37 SIRT1 deacetylates PGC1a and promotes nuclear
transfer.38 AMPK is a sensor of AMP/ATP ratio. At low energy
state, AMPK promotesPGC-1a phosphorylation and there-
fore regulates glucose transport, fatty acid oxidation and
mitochondrial biogenesis. TFAM controls the expression of
mtDNA replication and transcription, and participates in
mtDNA base excision repair process.39 Study has shown that
the expression of PGC-1a, NRF 1, NRF 2 and TFAM are
significantly decreased in the hippocampus of AD, sug-
gesting an abnormal mitochondrial biogenesis in AD.40
Interestingly, overexpression of PGC-1a can reduce the
mitochondrial damage and improve biogenesis.40Fig. 2 Mitochondrial dysfunctions interact with the pathological
drugs and technologies targeting mitochondria may relieve or preve
tetramethylpiperidine-1-oxyl,Nrf2: NF-E2-related factor 2,ARE: ant
amyloid b peptide, NFT: neurofibrillary tangles.)Resveratrol, one of the main active components of wine,
is a polyphenolic compound. Many studies have noted that
resveratrol can induce Sirt1 expression, increase AMPK
activation, and activate PGC-1a (Fig. 2B).41,42 Through
Sirt1, PGC-1a and P53 signaling, resveratrol reduces hip-
pocampal degeneration and learning impairment in AD
models.43 In vitro, resveratrol inhibits Ab-induced apoptosis
through Sirt.44 Long-term resveratrol diet reduces learning
and memory impairment, decreases amyloid and phos-
phorylated tau by activating AMPK and Sirt1.45 A recent
multicenter, randomized, double-blind, placebo-controlled
Phase II clinical trial for mild to moderate AD shows that
resveratrol is safe and well tolerated, and causes a certain
degree of AD biomarker changes (plasma and cerebrospinal
fluid Ab40).46 Resveratrol and glucose and malate mixed
drug are undergoing phase III clinical trial (NCT00678431),
which is expected to become a treatment choice for mild to
moderate AD.
PPAR (a, b/d, g) agonist bezafibrate is commonly used to
treat dyslipidemia. Recent research finds that PPARs can
regulate mitochondrial function through PGC-1a.47 Bezafi-
brate mainly activates PPARa, but also regulates PPARb and
PPARg activity.48 It is known that bezafibrate significantly
reduces tau protein level and microglia activation, pro-
motes mitochondrial biogenesis and improves behavioral
activities in P301S mice.49 In COX10 knockout mice, beza-
fibrate increases mitochondrial ATP synthesis, decreases
astrocyte proliferation and inflammatory factors,50 sug-
gesting a potential significance of bezafibrate in the
treatment of neurodegenerative diseases.
Thiazolidinedione drugs (TZDs) such as rosiglitazone,
pioglitazone that are PPARg agonists used for the treatment
of diabetes, have been shown to improve the awareness of
mild to moderate AD. Animal study shows that TZDs en-
hances mitochondrial biogenesis and respiratory function.51changes of Alzheimer’s disease, creating a vicious cycle. New
nt AD progression. (TPPþ: triphenylphosphine, TEMPO: 2,2,6,6-
ioxidant response element, TZDs: thiazolidinedione drugs, Ab:
224 J. Wang, G.-J. ChenTZDs also promotes b-amyloid plaque clearance, reduces
tau phosphorylation and improves synaptic plasticity.52
Clinical trials show that rosiglitazone increases whole-
brain glucose metabolism.53 Patients with mild AD or MCI
receiving six months of rosiglitazone (4 mg/day N Z 20)
exhibit better delayed recall (4 months and 6 months).54
Another study investigated the effect of rosiglitazone in
511 mild to moderate AD patients, in which rosiglitazone
significantly improves cognitive function in APOEε4 allele-
negative but not in APOEε4 allele-positive patients.55 A
recent prospective cohort study has shown that long-term
use of pioglitazone reduces the risk of dementia in pa-
tients of diabetes.56 A meta analysis suggests that PPARg
agonists, especially rosiglitazone may be beneficial for
early stages of mild to moderate AD, and the tolerability
has been widely praised.57Mitochondrial dynamics
Mitochondrial dynamics are also known as fission and
fusion. The dynamic changes regulate mitochondrial
morphology, which in turn can affect the mitochondrial
energy synthesis and quality control. In many neurode-
generative diseases, mitochondrial dynamics are
affected.58 Several proteins play important role in fission
and fusion. Mfn1, Mfn2, Opa1 are three main proteins
controlling mitochondrial fusion (Fig. 1C). The dimmeriza-
tion of Mfn1 and Mfn2 in the outer membrane and OPA1
localized in the inner membrane are shown to promote
membrane fusion.59 On the other hand, Drp1 and Fis1
contribute to fission. Drp1 (also known as Dlp1 and Dnm1) is
located in the cytoplasm and functions through self-
assembled spiral polymers to surround mitochondrial
membrane and uses GTP hydrolysis to initiate fission.60 Fis1
is responsible for recruiting Drp1 from cytoplasm to the
outer membrane.61
Manczak62 reports that in the frontal cortex of AD pa-
tients, Drp1 and Fis1 are increased at mRNA and protein
levels, while the fusion gene Mfn1, Mfn2 and OPA1
expression are significantly reduced, suggesting that the
imbalance of mitochondrial fission and fusion is an impor-
tant mechanism involved in neuronal dysfunction. Study has
shown that the interaction of Drp1 with Ab and tau may
cause excessive mitochondrial fission, resulting in synaptic
dysfunction and cognitive decline.63 A study by Reddy
et al.64 demonstrates that partial inhibition of Drp1 pre-
vents the toxic effects of Ab and tau, stables mitochondrial
dynamics and increases mitochondrial biogenesis and syn-
aptic activity. DRP1 is also found to be associated with
GSK3b, CDK5 and p53,64 but their relevance in AD has not
been exactly clarified. Overall, the close association of
Drp1 with Ab and tau suggests that Drp1 might serve as a
potential therapeutic target in AD.65
Mdivi-1, a Drp1 selective inhibitor, can inhibit Drp1 self-
assembly and GTP activity.66 Cells treated with mdivi-1
show anti-apoptotic properties presumably due to the in-
hibition of the mitochondrial membrane permeability.
Mdivi-1 alleviates apoptosis in tubular and acute kidney
injury through inhibiting mitochondrial fission.67 In addi-
tion, mdivi-1 has been widely studied in animals models of
epilepsy,68 ischemia,69 oxygen e glucose deprivation.70 Qiet al71 find that p110, another Drp1 peptidase inhibitor, can
block Drp1 activity and its interaction with Fis1, thereby
reduces mitochondrial fragmentation and ROS production,
and neurotoxicity. These findings suggest that mdivi-1
might have therapeutic effects in AD.Mitochondrial DNA mutations
Human mitochondrial DNA (mtDNA) contains a total of 37
genes, 13 of which are involved in oxidative phosphoryla-
tion (OXPHOS). In most cases, disease-causing mutations
are recessive. Clinical symptoms do not appear until
OXPHOS is damaged by a substantial proportion of muta-
tions.72 The muscle and brain tissues require high energy
and thus are particularly rich in mitochondria, in which
frequent mtDNA mutations may cause a variety of neuro-
muscular disorders. Unlike nuclear DNA (nDNA)that are
protected by histones,73 mtDNA are highly sensitive to
mutagenic and cytotoxic ROS, the mutations of which are
10 times more than those of nDNA. As a result, abnormal
products including NADH dehydrogenase, cytochrome C
oxidase (COX) and ATP synthase, would eventually cause
more electron leak and ROS generation. This so-called
“vicious circle” plays an important role in aging. A recent
mitochondrial gene polymorphism study demonstrates that
mitochondrial haplogroup may increase genetic suscepti-
bility to AD independent of APOE4.74 A technique called
pro-nuclear transfer has been developed to replace mtDNA
in female carriers with mtDNA mutations. The nuclear
chromosomes in her fertilized eggs can be transferred to a
new fertilized egg where its own nuclear chromosomes are
removed, so that the fertilized egg contains patient’s nDNA
and the new mtDNA derived from egg donors. Another
similar technique is to transfer nDNA in the egg before
being fertilized in vitro.75 While these technologies have
been successful in some animal experiments, the efficacy
and safety issues should be carefully addressed before
human clinical applications.
Pathogenic mtDNA mutation and wild-type mtDNA
coexist in the cell, known as heterogeneity.76 Current
mitochondrial gene therapy strategies aim to reduce the
pathogenic mtDNA to a below threshold level, which is to
increase the ratio of wild-type mtDNA to mutant mtDNA.
These measures include designing anti-gene sequences to
bind mutant mtDNA and inhibit its replication, or using
mitochondrial targeting nuclease such as peptide nucleic
acids, restriction enzymes and zinc-finger nuclease en-
zymes, to selectively degrade mutant mtDNA. The feasi-
bility of these methods has been validated in several animal
models, but many problems have not been solved. For
instance, the size of the carrier may inhibit mtDNA from
passing through inner mitochondrial membrane. In addi-
tion, mtDNA degradation is difficult to control, especially
for tissues and cells containing high levels of mtDNA mu-
tations.77 Some studies suggest that the use of retroviral
vector gene therapy may lead to upregulation of proto-
oncogene and cause malignant transformation of cells.78
Allotopic expression is another technique that uses nDNA
to express genes originally encoded by mitochondrial
genome (Fig. 1D). A section of exogenous DNA that encodes
the normal mtDNA is made to reintegrate into nDNA, and
Mitochondria as a therapeutic target in AD 225the gene products are then transported to mitochondria.
Using this method, Guy J et al79 have successfully repaired
the mutation (11778G> A) of ND4 subunit of complex I in
Leber hereditary optic neuropathy (LHON).Today the gene
therapy trials of allotopic expression for LHON are
recruiting patients.80 It is believed these gene therapy
strategies would provide important information for treating
AD and other neurodegenerative diseases.
Other treatments
Dimebon was first considered as blocking H1-histamine re-
ceptors,81 and was used to treat allergic diseases in the
early 1980s. Studies suggest that Dimebon is also an inhib-
itor of NMDA receptors and voltage-gated calcium chan-
nels,82 It maintains mitochondrial function by inhibiting
Ab25-35 induced mitochondrial permeability transition pore
(MPTP) opening.83 Clinical trial shows that Dimebon is safe
and effective, well tolerated, and dramatically improves
the clinical symptoms of mild-to-moderate AD.84 However,
in phase III clinical trials Dimebon fails to demonstrate a
significant effect.85
Melatonin, a major pineal hormone widely presented in
the cell, is considered as a powerful free radical scav-
enger.86 Study shows that melatonin upregulates anti-
apoptotic factor Bcl-2 expression, downregulates the
expression of pro-apoptotic Bax, inhibits Ab-induced cell
death and stabilizes mitochondrial function.86 Melatonin
also indirectly inhibits the opening of the mitochondrial
transition pore (MTP), blocks MTP-dependent cytochrome C
release. Transgenic AD mice receiving melatonin (10 mg/
kg) for 4 months exhibit reduced levels of oxidative stress
and pro-apoptotic markers.87 Long-term melatonin treat-
ment improves cognition in mice and reduces the expres-
sion of amyloid deposition and inflammatory cytokines.88
Clinical studies also reveal the therapeutic effect of
melatonin in AD.89,90
a-Tubulin deacetylation by histone deacetylase 6
(HDAC6) is a key factor to ensure axonal transport,
destruction of which is an important pathophysiological
process of AD. Studies show that HDAC6 inhibitor tubastatin
A restores Ab-induced dysfunction of axonal transport of
mitochondria,91 and HDAC6 knockout mice exhibit
improved learning and memory,92 suggesting that HDAC6
inhibitor may serve as a potential target for AD.
Conclusions
The exploration of mitochondrial targeting treatment still
remains in animal experiments. Many drugs that show
therapeutic effect in AD mouse model do not achieve the
desired results in clinical studies. The reason may be that
the majority of AD mice are constructed by amyloid depo-
sition, while the real development of the human disease
might be more complicated. In addition, as mitochondrial
dysfunction is an early manifestation of AD, it might be too
late to start drug therapy. AD is always diagnosed when
disease develops to the late stage, thus the early diagnosis
and preventive treatment should be very important.
Nonetheless, owing to the important role of mitochondria
in the pathophysiology of AD, we think that future therapytargeting mitochondria may open a new window in the
treatment for AD.
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